Notably, Novo Nordisk, a Danish pharmaceutical company, has recently developed the monoclonal antibody [MAb]3F52, which can specifically bind to the extracellular domain (ECD) Fab region of GLP-1R, and enabled the selective detection of GLP-1R in C57BL mice (43)
12 It is the first Health Canada approved treatment to support chronic weight management and to reduce the risk of non-fatal MI, and now, for the treatment of non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis)
That was the case this December, when the FDA approved an oral version of Wegovy, the first-ever oral GLP-1 medication specifically indicated for weight loss
This is very effective when used for short-term applications and is also very safe for use
However, the way a person loses weight also matters
10.1073/pnas.0506982103 351